BioN­Tech pays $20M up­front for two mon­o­clon­al an­ti­bod­ies from Chi­na's WuXi Bi­o­log­ics

BioN­Tech is pay­ing out $20 mil­lion up­front to an­oth­er Chi­nese part­ner in ex­change for the rights to de­vel­op two pre­clin­i­cal mon­o­clon­al an­ti­bod­ies, this time with CRD­MO WuXi Bi­o­log­ics.

The deal al­so in­cludes re­search, de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stone pay­ments, plus tiered roy­al­ties for the Shang­hai-based com­pa­ny, which will use its an­ti­body dis­cov­ery tech­nol­o­gy plat­forms to dis­cov­er the an­ti­bod­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER